Basis: Trailing twelve months (TTM). Source: stored company filings and market data; unavailable inputs remain N/A.
Is the EBITDA margin high or low?
The EBITDA margin of -16238.30% is 414% below its 3-year average of -3161.76%, near the high end of its 3-year range (-3032029.01%–-643.83%).
97.37% above its 12-month average of -618215.44%.
Reported quarterly EBITDA margin; no daily interpolation. Q4 FY2022 (2022-12-31): -3032029.01%.
EBITDA MARGIN
-16238.30%
EBITDA MARGIN AVG TTM
-618215.44%
EBITDA MARGIN AVG 3Y
-3161.76%
EBITDA MARGIN AVG 5Y
N/A
EBITDA MARGIN AVG 10Y
N/A
EBITDA MARGIN AVG 15Y
N/A
EBITDA MARGIN AVG 20Y
N/A
CURRENT VS TTM AVG
+97.37%
CURRENT VS 3Y AVG
-413.58%
CURRENT VS 5Y AVG
N/A
CURRENT VS 10Y AVG
N/A
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
Immuneering Corporation
Market Cap
$146.66M
EBITDA Margin
-16238.30%
TTM Avg
-618215.44%
3Y Avg
-3161.76%
5Y Avg
N/A
Market Cap
$149.51M
EBITDA Margin
-47.00%
TTM Avg
-68.63%
3Y Avg
-61.93%
5Y Avg
-48.63%
Market Cap
$143.81M
EBITDA Margin
-239.78%
TTM Avg
-210.59%
3Y Avg
-2213.91%
5Y Avg
-2345.87%
Market Cap
$142.49M
EBITDA Margin
-103.63%
TTM Avg
-143.63%
3Y Avg
-176.25%
5Y Avg
-194.05%
Market Cap
$142.11M
EBITDA Margin
-221.15%
TTM Avg
-221.15%
3Y Avg
-221.15%
5Y Avg
-221.15%
Market Cap
$152.16M
EBITDA Margin
-48812.58%
TTM Avg
-48812.58%
3Y Avg
-48812.58%
5Y Avg
-48812.58%
Market Cap
$153.84M
EBITDA Margin
-550.97%
TTM Avg
-275.49%
3Y Avg
-275.49%
5Y Avg
-275.49%
Market Cap
$138.26M
EBITDA Margin
-5.26%
TTM Avg
-11.06%
3Y Avg
-22.91%
5Y Avg
-20.50%
| NAME | MARKET CAP | EBITDA MARGIN | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Immuneering Corporation (IMRX) | $146.66M | -16238.30% | -618215.44% | -3161.76% | N/A |
| Codexis, Inc. (CDXS)vs › | $149.51M | -47.00% | -68.63% | -61.93% | -48.63% |
| Korsana Biosciences, Inc. (KRSA)vs › | $143.81M | -239.78% | -210.59% | -2213.91% | -2345.87% |
| Fortress Biotech, Inc. (FBIOP)vs › | $142.49M | -103.63% | -143.63% | -176.25% | -194.05% |
| Alpha Cognition Inc (ACOG)vs › | $142.11M | -221.15% | -221.15% | -221.15% | -221.15% |
| Cardiol Therapeutics Inc. (CRDL)vs › | $152.16M | -48812.58% | -48812.58% | -48812.58% | -48812.58% |
| Anavex Life Sciences Corp. (AVXL)vs › | $152.45M | N/A | N/A | N/A | N/A |
| Acumen Pharmaceuticals, Inc. (ABOS)vs › | $153.84M | -550.97% | -275.49% | -275.49% | -275.49% |
| KORU Medical Systems, Inc. (KRMD)vs › | $138.26M | -5.26% | -11.06% | -22.91% | -20.50% |
| LifeMD, Inc. (LFMDP)vs › | $155.88M | -0.19% | -1.66% | -11.02% | -42.72% |
Gross Margin
0.0%
EBITDA Margin
-16238.3%
Operating Margin
0.0%
Net Margin
0.0%
Formula: EBITDA Margin = (EBITDA / Revenue) × 100
Why EBITDA Margin matters:
EBITDA Margin = EBITDA / Revenue
EBITDA margin measures operating profitability before interest, taxes, depreciation, and amortization as a percentage of revenue.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | EBITDA MARGIN |
|---|---|
| 2022-12-31 | -3032029.01% |
| 2022-09-30 | -34165.60% |
| 2022-06-30 | -12120.11% |
| 2022-03-31 | -6927.15% |
| 2021-12-31 | -5835.33% |
| 2021-09-30 | -1764.22% |
| 2021-06-30 | -1205.35% |
| 2021-03-31 | -828.94% |
| 2020-12-31 | -876.44% |
| 2020-09-30 | -643.83% |
| 2020-06-30 | -748.85% |
| 2020-03-31 | -667.42% |
